Hong Kong is quickly becoming a hub for life-science technology companies, with 45 companies investing HK$6.5 billion (US$832 million) since last year. This surge in interest is due to Hong Kong’s advantages, including fundraising opportunities, cutting-edge research capabilities, robust policy support, and a diverse talent pool. Overseas companies are also pleased with the government’s funding incentives that support various stages of development.
![Hong Kong Chief Executive John Lee Ka-chiu (back row, fourth from left) and Financial Secretary Paul Chan Mo-po (on Lee’s right), attend the Oases Partnership Signing Ceremony at the central government office in Admiralty on March 20, 2024. Photo: Sam Tsang 480a55e9 d9a9 4dfd ba33 9c801d84e8cc 956c81a3](https://cdn.i-scmp.com/sites/default/files/d8/images/canvas/2024/05/08/480a55e9-d9a9-4dfd-ba33-9c801d84e8cc_956c81a3.jpg)
The city aims to continue attracting more companies, especially in the therapeutics sector. With its focus on cutting-edge research, Hong Kong is poised to make significant advancements in pharmaceutical research and development. Collaboration with mainland Chinese companies is also on the horizon, creating a win-win situation.